Stay at the forefront of the week’s champions and runners-up among publicly traded biotech companies and the reasons behind the ups or downs of their stock price fluctuations.
StockWatch appears weekly in GEN Edge. Subscribe today to GEN Edge, starting with our 30-Day Free Trial, and keep a leading edge on the competition.
Biogen (BIIB)’s second cost-cutting restructuring in five months . . .
See More on the Edge
Continue reading this article and more
with a GEN Edge subscription
The post StockWatch: Investors Unfazed by Biogen CEO Search, Aduhelm Cutbacks appeared first on GEN – Genetic Engineering and Biotechnology News.
